Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Board hears warning on specialty drugs: hepatitis C and new classes could sharply raise pharmacy spend
Summary
Aon Hewitt presented pharmacy trend analysis showing specialty drugs are a growing share of pharmacy spend (approx. 26%) and cited hepatitis C drugs as an example of rapid cost growth; the board requested plan‑specific dollar estimates and follow‑up reporting.
Board members heard a data‑driven briefing on pharmacy trends, with a focus on specialty drugs and pipeline therapies likely to increase near‑term pharmacy spend.
Dr. Paige Sipes Metzler (Aon Hewitt) told the board that specialty drugs accounted for roughly one‑quarter of pharmacy dollars while representing a very small share of prescriptions. Hepatitis C drugs were cited as a concrete example: therapies approved in late 2013 (sofosbuvir, ledipasvir/sofosbuvir)…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
